R5 is the API supplier’s third UK acquisition since 2006 and will complement its formulations capability while enabling it to consolidate and enhance its portfolio of pharmaceutical and biotechnology clients.
Aesica has an annual turnover in the region of £100m and employs 700 people. It is currently undergoing a period of expansion both in the UK and the US, where it has opened offices in San Diego and New York.
R5 develops and manufactures medicines and clinical trial materials and is a leading provider of pharmaceutical dosage form development across Europe. The firm will retain its current identity and brand and become a subsidiary of Aesica Pharmaceuticals. Key members of the Aesica team will join the board at R5. The expertise of the people at R5 will be utilised in its entirety and Aesica will provide support and investment moving forward.
Robert Hardy, chief executive of Aesica, said: ‘R5 has a proven track record in delivering early phase formulation development and its reputation within the emerging biotechnology industry was of particular interest, as we begin to increase our portfolio of clients within this field.’
Paul Titley, managing director of R5, added: ‘The all-inclusive service offering provided by Aesica is rare and we believe our early stage research and development experience will add a new and invaluable dimension to the business.’
